Merck has launched the Chemisphere app, a digital tool that enables scientists to easily access product documentation and ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen (QGEN – Research Report) and Merck & Company (MRK – Research Report). Claim 50% Off Ti ...

Merck & Co., Inc. (MRK), based in Rahway, New Jersey, is a healthcare company. Valued at $264.2 billion by market cap, the company delivers health solutions through its prescription medicines, ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $131.00. Chris Shibutani has given his Buy rating to Merck & ...

In the latest market close, Merck (MRK) reached $106.64, with a +0.28% movement compared to the previous day. The stock's change was more than the S&P 500's daily loss of 0.05%. Meanwhile, the Dow ...

In a report released on January 16, Steve Scala from TD Cowen maintained a Hold rating on Merck & Company, with a price target of $120.00. The company’s shares closed last Friday at $108.83. Scala ...

The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Merck (known as MSD outside of the United States and Canada) will complete its $9.2 billion acquisition of Cidara Therapeutics, bringing CD388, a late-stage flu antiviral, into its pipeline and aimed ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of ...

Merck (MRK) closed at $105.88 in the latest trading session, marking a -1.15% move from the prior day. This change lagged the S&P 500's 0.27% gain on the day. On the other hand, the Dow registered a ...